EUCTR2019-001957-16-SK进行中（未招募）1 期
Phase II study of Vinorelbine, cisplatin, disulfiram and copper in CTC_EMT positive refractory metastatic breast cancer.
árodný onkologický ústav0 个研究点目标入组 0 人开始时间: 2019年7月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1)Female patients with histologically confirmed carcinoma of the breast.
- •2)CTC_EMT positivity in the peripheral blood.
- •3)Patients with locally recurrent or metastatic, hormone receptor positive, HER2 negative disease HER2 negative who have received at least two (and not more than five) prior chemotherapeutic regimens for breast cancer, at least two of which were administered for treatment of locally recurrent and/or metastatic disease.
- •4)Prior therapy must be documented by the following criteria prior to entry onto study:
- •-Regimens must have included an anthracycline (eg., doxorubicin, epirubicin) and a taxane (e.g., paclitaxel, docetaxel) in any combination or order. Treatment with any of these agents is not required if they are contraindicated for a certain patient.
- •-One or two of these regimens may have been administered as adjuvant and/or neoadjuvant therapy, but at least 2 must have been given for relapsed or metastatic disease.
- •-Patients must have proved refractory to the most recent chemotherapy, documented by progression on or within six (6) months of therapy.
- •5)Patients may have additionally been treated with anti-hormonal therapy.
- •6)Resolution of all chemotherapy or radiation-related toxicities to Grade 1 severity or lower, except for stable sensory neuropathy <= Grade 2 and alopecia.
- •7)Age >= 18 years.
- •8)Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2.
- •9)Life expectancy of >= 3 months.
- •10)Adequate renal function as evidenced by calculated creatinine clearance >= 40 mL/min per the Cockcroft and Gault formula.
- •11)Adequate bone marrow function as evidenced by absolute neutrophil count (ANC) >= 1.5 x 10^9/L, hemoglobin >= 9.0 g/dL (a hemoglobin <10.0 g/dL is acceptable if it is corrected by growth factor or transfusion), and platelet count >= 100 x 10^9/L.
- •12)Adequate liver function as evidenced by bilirubin <= 1.5 times the upper limits of normal (ULN) and alkaline phosphatase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) <= 3 x ULN (in the case of liver metastases <= 5 x ULN), unless there are bone metastases, in which case liver specific alkaline phosphatase must be separated from the total and used to assess the liver function instead of the total alkaline phosphatase. In case alkaline phosphatase is >3 x ULN (in absence of liver metastases) or > 5 x ULN (in presence of liver metastases) AND patient is known to have bone metastases, the liver specific alkaline phosphatase must be separated from the total and used to assess the liver function instead of the total alkaline phosphatase.
- •13)Patients willing and able to comply with the study protocol for the duration of the study.
- •14)Written informed consent prior to any study-specific screening procedures with the understanding that the patient may withdraw consent at any time without prejudice.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 28
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 28
排除标准
- •1)Patients who have received any of the following treatments within the specified period before study treatment start: chemotherapy, radiation, trastuzumab or hormonal therapy within three weeks, any investigational drug within four weeks, radiation therapy encompassing > 30% of marrow.
- •2)Addiction to alcohol or drugs.
- •3)Need for metronidazole, warfarin and/or theophylline medication, the metabolism of which is likely influenced by disulfiram and copper, see Table 4.
- •4)Patients who are taking medications metabolized by cytochrome P450 2E1, including chlorzoxazone or halothane and its derivatives, see Table 4..
- •5)Pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring active treatment, including the use of oxygen.
- •6)Patients with brain or subdural metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least 4 weeks before starting treatment in this study. Any signs (eg., radiologic) and/or symptoms of brain metastases must be stable for at least 4 weeks before starting study treatment; radiographic stability should be determined by comparing a contrast-enhanced computed tomography or magnetic resonance imaging brain scan performed during screening to a prior scan performed at least 4 weeks earlier.
- •7)Patients with meningeal carcinomatosis.
- •8)Women who are pregnant or breast-feeding; women of childbearing potential with either a positive pregnancy test at screening or no pregnancy test; women of childbearing potential unless (1) surgically sterile or (2) using adequate measures of contraception in the opinion of the Investigator. Perimenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential.
- •9)Severe/uncontrolled intercurrent illness/infection.
- •10)Patients with organ allografts requiring immunosuppression.
- •11)Patients with known positive HIV status.
- •12)Hemochromatosis.
- •13)Patients who have had a prior malignancy, other than previous breast cancer, carcinoma in situ of the cervix, or non-melanoma skin cancer, unless the prior malignancy was diagnosed and definitively treated >= 5 years previously with no subsequent evidence of recurrence.
- •14)Patients with pre-existing neuropathy > Grade 2.
- •15)Patients with other significant disease or disorders that, in the Investigator's opinion, would exclude the patient from the study.
研究者
相似试验
撤回
2 期
Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.Metastatic Breast CancerNCT04265274National Cancer Institute, Slovakia
已完成
1 期
Phase I study of Vinorelbine(VNR) and S-1 combination therapy for the elderly patients with advanced non-small-cell lung cancer.advanced non-small-cell lung cancerJPRN-UMIN000026093Tokyo Metropolitan Tama Medical Center Department of respiratory medicine and clinical oncology9
进行中（未招募）
不适用
Fase II study of carboplatin and vinorelbine in malignant pleural mesothelioma - Fase II MPMPatients with malignant pleural mesothelioma who cannot be operatedEUCTR2005-002223-14-DKRigshospitalet40
进行中（未招募）
1 期
Study to evaluate effectiveness of disulfiram and cisplatin in patients with refractory testicular cancer.platina refractory testicular germ cell cancerMedDRA version: 20.0 Level: PT Classification code 10061184 Term: Germ cell cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-000558-68-SKárodný onkologický ústav20
进行中（未招募）
1 期
Phase II study evaluating oral vinorelbine as a single agent in patients with hormone receptor breast cancer with bone metastases previously treated by a hormone therapyBreast cancer with bone metastases previously treated by a hormone therapy.MedDRA version: 12.1Level: LLTClassification code 10027475Term: <Manually entered code. Term in E.1.1>EUCTR2009-014497-18-FRPIERRE FABRE MEDICAMENT66